Next Article in Journal
Development of a New Positron Emission Tomography Tracer for Targeting Tumor Angiogenesis: Synthesis, Small Animal Imaging, and Radiation Dosimetry
Previous Article in Journal
Three New Multiflorane-Type Triterpenes from Pumpkin (Cucurbita maxima) Seeds
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 18
Issue 5
10.3390/molecules18055580
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones

by
Baoxiang Hu
1,
Xiaochu Zhang
1,
Lili Sheng
1,
Ming Guo
2,
Zhenlu Shen
1,*,
Xinquan Hu
1,
Nan Sun
1 and
Weimin Mo
1,*
1
State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology, College of Chemical Engineering and Materials Science, Zhejiang University of Technology, Hangzhou 310014, China
2
Department of Chemistry, Zhejiang Agriculture & Forestry University, Lin'An 311300, China
*
Authors to whom correspondence should be addressed.
Molecules 2013, 18(5), 5580-5593; https://doi.org/10.3390/molecules18055580
Submission received: 25 March 2013 / Revised: 12 May 2013 / Accepted: 13 May 2013 / Published: 15 May 2013
(This article belongs to the Section Organic Chemistry)
Browse Figure
Versions Notes

Abstract

:
A hexachlorocyclotriphosphazene (HCCP)-mediated direct formation of quinazoline (thio)ethers from quinazolin-4(3H)-ones has been developed. Treatment of quinazolin-4(3H)-ones with HCCP, diisopropylethylamine (DIPEA), and thiophenols resulted in formation of the corresponding 4-arylthioquinazoline derivatives in moderate to excellent yields. This method has also been utilized to prepare 4-aryloxyquinazoline and 4-alkoxyquinazoline derivatives using phenols and sodium alkoxides as the nucleophiles.

1. Introduction

Quinazoline derivatives are an important class of nitrogen-containing heterocycles. They have attracted interest in the past because of their varied biological activities, such as anticonvulsant, antihypertensive, vasodilator, antiinflammatory, antibiosis, fibrinogen receptor antagonistic and nanomolar Hedgehog-antagonistic properties [1,2,3,4,5,6,7,8]. Among the family of quinazolines, quinazoline (thio)ethers, including 4-arylthioquinazolines and 4-aryloxyquinazolines, have received considerable interest because of their potential pharmacological activity [9,10,11,12,13,14,15,16].
Generally, 4-arylthioquinazolines and 4-aryloxyquinazolines are obtained through SNAr substitution of electron-deficient 4-chloroquinazolines with the appropriate thiophenols or phenols in the presence of a base [9,10,11,12,13,14,15,16,17,18,19]. The common method for preparation of 4-chloroquinazolines is the chlorination of corresponding quinazolin-4(3H)-ones. The chlorination reagents used include SOCl2, POCl3, PCl5 or their combinations, and the chlorination reactions are usually performed under harsh conditions. However, these chlorination reagents are not environmentally friendly, and some sensitive functional groups may be destroyed under the chlorination conditions. In addition, many 4-chloroquinazoline derivatives are moisture sensitive, thus special treatments are required for their purification and storage.
In order to avoid the use of chlorination reagents and an individual activation step, an in situ activation of quinazolin-4(3H)-ones is highly desirable. Phosphonium compounds, such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), have been developed to activate quinazolin-4(3H)-ones and successfully employed in the synthesis of 4-aminoquinazolines, 4-arylthioquinazolines and 4-aryloxyquinazolines using amine, thiophenol and phenol nucleophiles, respectively [20,21]. However, BOP and other phosphonium reagents are expensive, moreover, utilization of BOP generates as an end product HMPA, a highly carcinogenic chemical.
As a part of our research program focused on quinazoline chemistry [22,23], we have recently, reported that hexachlorocyclotriphosphazene (Cl6N3P3, HCCP) can be used as an inexpensive and readily available activating reagent in the direct amination of quinazolin-4(3H)-ones (1) [24]. In the reaction, quinazolin-4(3H)-ones are activated in situ with HCCP to generate the highly reactive phosphonium intermediate 2, then amines can nucleophilically attack 2 to form 4-aminoquinazolines. Thus, we speculated that other nucleophiles, such as thiophenol and phenol ones, might attack 2 to form the corresponding products. Herein, we report a HCCP-mediated, single-pot, facile synthesis of thioethers and ethers from quinazolin-4(3H)-ones in moderate to excellent yields (Scheme 1).
Molecules 18 05580 g001 550
Scheme 1. One-pot synthesis of quinazoline (thio)ethers from quinazolin-4(3H)-ones mediated by HCCP.
Scheme 1. One-pot synthesis of quinazoline (thio)ethers from quinazolin-4(3H)-ones mediated by HCCP.
Molecules 18 05580 g001

2. Results and Discussion

Initially, the reaction of quinazolin-4(3H)-one (1a) and thiophenol was investigated as the model reaction to establish the feasibility of the strategy and to optimize the reaction conditions. The effects of solvent, base, temperature and HCCP loading, etc., were evaluated for this model reaction, and the results are summarized in Table 1.
Table
Table 1. Optimization of reaction conditions a. Molecules 18 05580 i055
Table 1. Optimization of reaction conditions a. Molecules 18 05580 i055
EntryBaseSolventTemperature (°C)Yield (%) b
1TEAMeCN4548
2K2CO3MeCN4532
3Cs2CO3MeCN4569
4DIPEAMeCN4581
5DIPEATHF4512
6DIPEADMF4523
7DIPEACH2Cl2457
8DIPEAMeCN4576 c
9DIPEAMeCN2568
10DIPEAMeCN6555
11DIPEAMeCN4579 d
12DIPEAMeCN4571 e
13DIPEAMeCN4581 f
14DIPEAMeCN4570 g
a Conditions: 1a (0.5 mmol), HCCP (1.1 equiv.), base (5.0 equiv.), solvent (5 mL), rt, activation time (1 h), then thiophenol (6.0 equiv.), 45 °C, 23 h; b Isolated yield; c HCCP (1.0 equiv.); d Thiophenol (5.0 equiv.); e Thiophenol (4.0 equiv.); f DIPEA (6.0 equiv.); g DIPEA (4.0 equiv.).
Compared with triethylamine (TEA), K2CO3 and Cs2CO3 (entries 1–3), diisopropylethylamine (DIPEA) was found to be the most effective in the model reaction of 1a and thiophenol (entry 4). The results in Table 1 show that the solvent can greatly affect the reaction, and acetonitrile led to much better yield of product 3 than tetrahydrofuran, N,N-dimethylformamide or dichloromethane (entries 4–7). According to Scheme 1, 1.0 equiv. HCCP loading was enough, but we found that increasing the HCCP loading from 1.0 to 1.1 equiv. resulted in 5% yield increases (entry 8 versus entry 4). After in situ activation of 1a with HCCP at room temperature for 1 h, the SNAr substitution of phosphonium intermediate 2a (R1 = H) with thiophenol was performed at 45 °C. At both lower and higher temperature, the yield of 3 decreased (entries 9 and 10). Like the HCCP-mediated direct amination of quinazolin-4(3H)-ones with amines [24], when the thiophenol nucleophile attacks 2a, two competitive SNAr substitutions were possible, either on the C–O bond or P–Cl bond. Thus, five to six equiv. of thiophenol and DIPEA were needed in this reaction. It was found variation of the amount of thiophenol or DPIEA from 6.0 equiv. to 5.0 equiv. did not significantly change the results (entry 4 versus entries 11 and 13), whereas upon decreasing the amount of thiophenol or DPIEA to 4.0 equiv., the yield of 3 was obviously decreased (entries 12 and 14). On the basis of these experimental data, the optimal reaction conditions were: 1.1 equiv. of HCCP, 5.0 equiv. of DIPEA, 5.0 equiv. of thiophenol, 45 °C of reaction temperature and acetonitrile as the reaction solvent, and these were employed in the following studies.
The results of HCCP-mediated direct formation of thioethers (4-arylthioquinazolines) from 1 and thiophenols are summarized in Table 2. Different substituted thiophenols smoothly reacted with 1a to afford the desired 4-arylthioquinazolines in moderate to excellent yields (entries 1–9). When o, m, and p-methoxythiophenols were used as the nucleophiles, o-methoxythiophenol gave the highest product yield, while m-methoxythiophenol showed the lowest reactivity (entries 4–6). It is noteworthy that chlorothiophenols, which usually exhibit lower nucleophilicity than methoxythiophenols, could conveniently undergo the transformation and gave excellent product yields in this HCCP-mediated direct formation of 4-arylthioquinazolines (entries 7 and 9). The reactions between thiophenol and a variety of substituted quinazolin-4(3H)-ones were also investigated. An array of substituted quinazolin-4(3H)-ones were suitable for this HCCP-mediated formation of thioethers and gave the desired 4-arylthioquinazolines in moderate to good yields (entries 1, 10–15). When 5-methylquinazolin-4(3H)-one (1b) and 5-chloroquinazolin-4(3H)-one (1e) were used as the substrates, activation time should be prolonged (entries 10 and 13).
Table
Table 2. HCCP-mediated formation of quinazoline thioethers from quinazolin-4(3H)-ones a. Molecules 18 05580 i056
Table 2. HCCP-mediated formation of quinazoline thioethers from quinazolin-4(3H)-ones a. Molecules 18 05580 i056
EntryQuinazolin-4(3H)-oneArSHProductYield (%) b
1 Molecules 18 05580 i0011a Molecules 18 05580 i011 Molecules 18 05580 i023379
21a Molecules 18 05580 i034 Molecules 18 05580 i041464 c
31a Molecules 18 05580 i042 Molecules 18 05580 i043569
41a Molecules 18 05580 i044 Molecules 18 05580 i045659
51a Molecules 18 05580 i002 Molecules 18 05580 i003750
61a Molecules 18 05580 i004 Molecules 18 05580 i005886
71a Molecules 18 05580 i006 Molecules 18 05580 i036994
81a Molecules 18 05580 i057 Molecules 18 05580 i0071066
91a Molecules 18 05580 i008 Molecules 18 05580 i0091191
10 Molecules 18 05580 i0101b Molecules 18 05580 i012 Molecules 18 05580 i0131254 d
11 Molecules 18 05580 i0141c Molecules 18 05580 i015 Molecules 18 05580 i0161360
12 Molecules 18 05580 i0171d Molecules 18 05580 i018 Molecules 18 05580 i0191464
13 Molecules 18 05580 i0201e Molecules 18 05580 i021 Molecules 18 05580 i0221551 d
14 Molecules 18 05580 i0241f Molecules 18 05580 i025 Molecules 18 05580 i0261679
15 Molecules 18 05580 i0271g Molecules 18 05580 i028 Molecules 18 05580 i0291772
aReagents andConditions: 1 (0.5 mmol), HCCP (1.1 equiv.), DIPEA (5.0 equiv.), MeCN (5 mL), rt, activation time (1 h), then thiophenols (5.0 equiv.), 45 °C, 23 h; b Isolated yield; cm-CH3PhSH (6.0 equiv.); reaction time (48 h); d Activation time (20 h).
The method was further extended to the synthesis of 4-aryloxyquinazolines through the reaction of 1 and phenols under the same reaction conditions (Table 3). Different phenols (phenol, m-methylphenol, o-chlorophenol and p-chlorophenol) could react with 1b and afforded the corresponding products 18–21 in moderate to good yields (entry 1–5). There is no significant electronic effect of substituents for products. Substituted quinazolin-4(3H)-ones were also used as the substrates to react with phenol. 6-Chloroquinazolin-4(3H)-one (1f) and 7-chloroquinazolin-4(3H)-one (1g) gave products 14 and 15 in 70% yield (entries 6 and 7), whereas in the case of 5-methylquinazolin-4(3H)-one (1b), the product 12 was obtained in 54% yield (entry 5). Alcohols were also used as the nucleophiles in this reaction. Unfortunately, no desired 4-alkoxyquinazolines were formed. It might be due to that the nucleophilicity of alcohols was too weak to undego SNAr substitution. Thus, sodium alkoxides were further utilized as the nucleophiles in this reaction to give the corresponding 4-alkoxyquinazolines (Table 3). When 1a, 8-methylquinazolin-4(3H)-one (1d) and 1g reacted with sodium ethoxide for 3 h, the yields of products 4-ethoxyquinazolines were 54%, 64% and 67%, respectively (entries 8,10 and 11), while 1b gave only 33% product yield (entry 9). 4-Propoxyquinazoline (29) could be obtained in 48% yield in the reaction between 1a and sodium propoxide (entry 12).
Table
Table 3. HCCP-mediated formation of quinazoline ethers from quinazolin-4(3H)-ones a. Molecules 18 05580 i058
Table 3. HCCP-mediated formation of quinazoline ethers from quinazolin-4(3H)-ones a. Molecules 18 05580 i058
EntryQuinazolin-4(3H)-oneArOH or RONaProductYield (%) b
11a Molecules 18 05580 i030 Molecules 18 05580 i0311875
21a Molecules 18 05580 i032 Molecules 18 05580 i0331952
31a Molecules 18 05580 i035 Molecules 18 05580 i0372073
41a Molecules 18 05580 i038 Molecules 18 05580 i0392151
51b Molecules 18 05580 i040 Molecules 18 05580 i0462253 c
61f Molecules 18 05580 i047 Molecules 18 05580 i0492370
71g Molecules 18 05580 i048 Molecules 18 05580 i0592470
81aCH3CH2ONa Molecules 18 05580 i0502554
91bCH3CH2ONa Molecules 18 05580 i0512633 c
101dCH3CH2ONa Molecules 18 05580 i0522767
111gCH3CH2ONa Molecules 18 05580 i0532864
121aCH3CH2CH2ONa Molecules 18 05580 i0542948
a Reagents and Conditions: 1 (0.5 mmol), HCCP (1.1 equiv.), DIPEA (5.0 equiv.), MeCN (5 mL), rt, activation time (1 h), then phenols (5.0 equiv.), 45 °C, 23 h; or R2ONa (5.0 equiv.), 45 °C, 3 h; b Isolated yield; c Activation time (20 h).

3. Experimental

3.1. General

1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra were obtained on a Bruker Avance III spectrometer. CDCl3 and DMSO-d6 were used as the solvent with tetramethylsilane (TMS) as the internal standard. Low and high resolution mass spectra were recorded in the ESI mode on an Agilent 6210 LC/TOF mass spectrometer. Melting points were measured using XRL-1 melting point instrument and are uncorrected. Quinazolin-4(3H)-ones were synthesized from anthranilic acids and formamidine acetate, and their structures were confirmed by MS, 1H-NMR, and 13C-NMR. Other reagents were purchased from supplier and used without any further treatment.

3.2. General Procedure for HCCP-Mediated Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones

Quinazolin-4(3H)-ones (1, 0.5 mmol), HCCP (171.2 mg, 0.55 mmol, 1.1 equiv.), DIPEA (323.8 mg, 2.5 mmol, 5 equiv.), and CH3CN (5 mL) were added to a nitrogen purged vial. The reaction mixture was stirred at room temperature for 1 h as activation time. Then nucleophile (2.5 mmol, 5 equiv. was added, and the reaction mixture was stirred at 45 °C for 23 h. The reaction mixture was partially concentrated under reduced pressure. The crude product was separated on a silica gel plate with ethyl acetate–hexane (1:10 or 1:5) as eluent. Then the area corresponding to the product was scraped off the TLC plate, and extracted with dichloromethane. The extract was concentrated to afford the corresponding products (3–29).
4-(Phenylthio)quinazoline (3). White solid (79% yield); mp 109–110 °C; 1H-NMR (DMSO-d6) δ 8.84 (s, 1H), 8.27 (d, J = 8.5 Hz, 1H), 8.07–8.04 (m, 1H), 8.00–7.99 (m, 1H), 7.83–7.79 (m, 1H), 7.68–7.66 (m, 2H), 7.56–7.54 (m, 3H); 13C-NMR (DMSO-d6) δ 170.3, 153.5, 147.8, 135.8, 134.6, 129.9, 129.6, 128.5, 128.4, 126.5, 123.6, 122.3; HRMS (ESI), m/z, 239.0644 [MH+], calcd for C14H11N2S, 239.0643.
4-(m-Tolylthio)quinazoline (4). White solid (64% yield); mp 58–61 °C; 1H-NMR (DMSO-d6) δ 8.83 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.05–8.02 (m, 1H), 7.99–7.97 (m, 1H), 7.81–7.77 (m, 1H), 7.48–7.41 (m, 3H), 7.36–7.35 (m, 1H), 2.37 (s, 3H); 13C-NMR (DMSO-d6) δ 170.5, 153.5, 147.8, 139.0, 136.0, 134.6, 132.9, 130.6, 129.4, 128.5, 128.3, 126.2, 123.6, 122.4, 20.7; HRMS (ESI), m/z, 253.0795 [MH+], calcd for C15H13N2S, 253.0799.
4-(p-Tolylthio)quinazoline (5) White solid (69% yield); mp 104–105 °C; 1H-NMR (DMSO-d6) δ 8.81 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.02–7.98 (m, 1H), 7.96–7.95 (m, 1H), 7.77–7.73 (m, 1H), 7.50–7.48 (m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 2.38 (s, 3H); 13C-NMR (DMSO-d6) δ 170.6, 153.4, 147.7, 139.7, 135.7, 134.4, 130.1, 128.4, 128.2, 123.4, 122.9, 122.3, 20.8; HRMS (ESI), m/z, 253.0798 [MH+], calcd for C15H13N2S, 253.0799.
4-(2-Methoxyphenylthio)quinazoline (6). White solid (59% yield); mp 111–113 °C; 1H-NMR (DMSO-d6) δ 8.80 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.04–8.01 (m, 1H), 7.98–7.96 (m, 1H), 7.80–7.76 (m, 1H), 7.60–7.54 (m, 2H), 7.20 (d, J = 8.0 Hz, 1H), 7.10–7.07 (m, 1H), 3.74 (s, 3H); 13C-NMR (DMSO-d6) δ 170.0, 160.0, 153.5, 147.8, 137.5, 134.4, 132.2, 128.4, 128.2, 123.7, 122.5, 121.2, 114.2, 112.3, 55.9; HRMS (ESI), m/z, 269.0747 [MH+], calcd for C15H13N2OS, 269.0749.
4-(3-Methoxyphenylthio)quinazoline (7). White solid (50% yield); mp 80–82 °C; 1H-NMR (DMSO-d6) δ 8.86 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.06–8.03 (m, 1H), 8.00–7.98 (m, 1H), 7.81–7.78 (m, 1H), 7.47–7.44 (m, 1H), 7.24–7.22 (m, 2H), 7.14–7.11 (m, 1H), 3.80 (s, 3H); 13C-NMR (DMSO-d6) δ 170.3, 159.7, 153.5, 147.8, 134.6, 130.3, 128.5, 128.3, 127.8, 127.5, 123.5, 122.4, 120.9, 115.7, 55.3; HRMS (ESI), m/z, 269.0746 [MH+], calcd for C15H13N2OS, 269.0749.
4-(4-Methoxyphenylthio)quinazoline (8). White solid (86% yield); mp 125–128 °C; 1H-NMR (DMSO-d6) δ 8.82 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.04–8.01 (m, 1H), 7.98–7.96 (m, 1H), 7.80–7.77 (m, 1H), 7.57–7.54 (m, 2H), 7.10–7.09 (m, 2H), 3.84 (s, 3H); 13C-NMR (DMSO-d6) δ 171.1, 160.7, 153.5, 147.7, 137.6, 134.6, 128.4, 128.3, 123.6, 122.3, 116.6, 115.3, 55.4; HRMS (ESI), m/z, 269.0739 [MH+], calcd for C15H13N2OS, 269.0749.
4-(2-Chlorophenylthio)quinazoline (9). White solid (94% yield); mp 124–126 °C; 1H-NMR (DMSO-d6) δ 8.85 (s, 1H), 8.29 (d, J = 8.0 Hz, 1H), 8.08–8.05 (m, 1H), 8.02–8.00 (m, 1H), 7.84–7.80 (m, 2H), 7.74–7.72 (m, 1H), 7.62–7.59 (m, 1H), 7.52–7.49 (m, 1H); 13C-NMR (DMSO-d6) δ 168.9, 153.4, 147.9, 138.8, 138.4, 134.7, 132.2, 130.3, 128.51, 128.47, 128.2, 125.9, 123.6, 122.3; HRMS (ESI), m/z, 273.0244 [MH+], calcd for C14H10ClN2S, 273.0253.
4-(3-Chlorophenylthio)quinazoline (10). White solid (66% yield); mp 125–126 °C; 1H-NMR (DMSO-d6) δ 8.86 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.04–8.03 (m, 1H), 8.00–7.98 (m, 1H), 7.81–7.76 (m, 2H), 7.65–7.61 (m, 2H), 7.58–7.55 (m, 1H); 13C-NMR (DMSO-d6) δ 169.7, 153.4, 147.9, 135.0, 134.7, 134.4, 133.6, 131.1, 129.9, 128.8, 128.5, 128.4, 123.5, 122.3; HRMS (ESI), m/z, 273.0243 [MH+], calcd for C14H10ClN2S, 273.0253.
4-(4-Chlorophenylthio)quinazoline (11). White solid (91% yield); mp 133-134 °C; 1H-NMR (DMSO-d6) δ 8.85 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.07–8.03 (m, 1H), 8.00–7.99 (m, 1H), 7.82–7.79 (m, 1H), 7.70–7.67 (m, 2H), 7.62–7.60 (m, 2H); 13C-NMR (DMSO-d6) δ 169.9, 153.4, 147.8, 137.5, 135.0, 134.7, 129.6, 128.5, 128.4, 125.5, 123.5, 122.3; HRMS (ESI), m/z, 273.0240 [MH+], calcd for C14H10ClN2S, 273.0253.
5-Methyl-4-(phenylthio)quinazoline (12). White solid (54% yield); mp 131–133 °C; 1H-NMR (DMSO-d6) δ 8.66 (s, 1H), 7.85–7.82 (m, 1H), 7.80–7.78 (m, 1H), 7.62–7.57 (m, 3H), 7.55–7.52 (m, 3H), 3.07 (s, 3H); 13C-NMR (DMSO-d6) δ 171.3, 152.2, 150.2, 135.9, 135.4, 133.4, 130.8, 129.7, 129.5, 128.2, 127.0, 123.4, 24.7; HRMS (ESI), m/z, 253.0790 [MH+], calcd for C15H13N2S, 253.0799.
6-Methyl-4-(phenylthio)quinazoline (13). White solid (60% yield); mp 100–102 °C; 1H-NMR (DMSO-d6) δ 8.83 (s, 1H), 8.00 (s, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.67–7.65 (m, 2H), 7.52–7.51 (m, 3H), 2.62 (s, 3H); 13C-NMR (DMSO-d6) δ 170.4, 153.3, 146.9, 137.9, 136.0, 135.8, 129.7, 129.4, 128.6, 127.4, 123.3, 122.7, 21.8; HRMS (ESI), m/z, 253.0796 [MH+], calcd for C15H13N2S, 253.0799.
8-Methyl-4-(phenylthio)quinazoline (14). White solid (64% yield); mp 98–100 °C; 1H-NMR (DMSO-d6) δ 8.84 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 7.0 Hz, 1H), 7.65–7.62 (m, 3H), 7.54-7.53 (m, 3H), 2.66 (s, 3H); 13C-NMR (DMSO-d6) δ 170.3, 152.6, 146.8, 136.7, 135.7, 134.2, 129.7, 129.5, 127.7, 126.8, 122.2, 121.1, 17.0; HRMS (ESI), m/z, 253.0789 [MH+], calcd for C15H13N2S, 253.0799.
5-Chloro-4-(phenylthio)quinazoline (15). White solid (51% yield); mp 133–134 °C; 1H-NMR (CDCl3) δ 8.73 (s, 1H), 7.91–7.89 (m, 1H), 7.74–7.68 (m, 2H), 7.60–7.58 (m, 2H), 7.51–7.50 (m, 3H); 13C-NMR (CDCl3) δ 172.5, 153.2, 151.3, 135.9, 132.7, 130.6, 129.9, 129.7, 129.4, 129.3, 128.5, 122.6; HRMS (ESI), m/z, 273.0244 [MH+], calcd for C14H10ClN2S, 273.0253.
6-Chloro-4-(phenylthio)quinazoline (16). White solid (79% yield); mp 103–105 °C; 1H-NMR (CDCl3) δ 8.86 (s, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 7.83-7.81 (m, 1H), 7.66–7.64 (m, 2H), 7.53–7.51 (m, 3H); 13C-NMR (CDCl3) δ 170.7, 154.0, 146.9, 135.8, 134.8, 133.3, 130.5, 130.0, 129.5, 126.7, 123.8, 122.9; HRMS (ESI), m/z, 273.0241 [MH+], calcd for C14H10ClN2S, 273.0253.
7-Chloro-4-(phenylthio)quinazoline (17). White solid (72% yield); mp 142–143 °C; 1H-NMR (DMSO-d6) δ 8.85 (s, 1H), 8.29 (d, J = 9.0 Hz, 1H), 8.07 (d, J = 2.0 Hz, 1H), 7.83–7.81 (m, 1H), 7.67–7.66 (m, 2H), 7.57–7.55 (m, 3H); 13C-NMR (DMSO-d6) δ 170.7, 154.5, 148.6, 139.2, 135.7, 130.0, 129.6, 128.9, 127.3, 126.1, 125.7, 121.0; HRMS (ESI), m/z, 273.0255 [MH+], calcd for C14H10ClN2S, 273.0253.
4-Phenoxyquinazoline (18). White solid (75% yield); mp 123–125 °C; 1H-NMR (CDCl3) δ 8.80 (s, 1H), 8.42–8.40 (m, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.96–7.94 (m, 1H), 7.69 (t, J =1.0 Hz, 1H), 7.54–7.50 (m, 2H), 7.37–7.35 (m, 1H), 7.30–7.28 (m, 2H); 13C-NMR (CDCl3) δ 167.0, 154.4, 152.4, 151.7, 134.2, 129.8, 128.0, 127.6, 126.1, 123.7, 121.9, 116.5; HRMS (ESI), m/z, 223.0868 [MH+], calcd for C14H11N2O, 223.0871.
4-(m-Tolyloxy)quinazoline (19). White solid (52% yield); mp 100–101 °C; 1H-NMR (CDCl3) δ 8.81 (s, 1H), 8.41–8.39 (m, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.95–7.92 (m, 1H), 7.70–7.67 (m, 1H), 7.41–7.38 (d, J = 7.5 Hz, 1H), 7.17–7.08 (m, 3H), 2.44 (s, 3H); 13C-NMR (CDCl3) δ 167.1, 154.4, 152.3, 151.6, 140.1, 134.1, 129.5, 127.9, 127.6, 126.9, 123.7, 122.4, 118.8, 116.5, 21.4; HRMS (ESI), m/z, 237.1025 [MH+], calcd for C15H13N2O, 237.1028.
4-(2-Chlorophenoxy)quinazoline (20). White solid (73% yield); mp 118–119 °C; 1H-NMR (CDCl3) δ 8.78 (s, 1H), 8.46–8.45 (m, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.98–7.96 (m, 1H), 7.74–7.72 (m, 1H), 7.57–7.56 (m, 1H), 7.43–7.41 (m, 1H), 7.38–7.36 (m, 1H), 7.34–7.32 (m, 1H); 13C-NMR (CDCl3) δ 166.2, 154.1, 151.9, 148.6, 134.3, 130.7, 128.1, 128.0, 127.8, 127.31, 127.26, 124.1, 123.7, 116.1; HRMS (ESI), m/z, 257.0479 [MH+], calcd for C14H10ClN2O, 257.0482.
4-(4-Chlorophenoxy)quinazoline (21). White solid (51% yield); mp 105–108 °C; 1H-NMR (CDCl3) δ 8.79 (s, H), 8.39 (d, J = 8.0 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.97–7.94 (m, 1H), 7.72–7.69 (m, 1H), 7.49–7.46 (m, 2H), 7.28–7.23 (m, 2H); 13C-NMR (CDCl3) δ 116.8, 154.1, 151.8, 150.9, 134.3, 131.5, 129.9, 128.0, 127.8, 123.5, 123.3, 116.3; HRMS (ESI), m/z, 257.0469 [MH+], calcd for C14H10ClN2O, 257.0482.
5-Methyl-4-phenoxyquinazoline (22). White solid (53% yield); mp 73–75 °C; 1H-NMR (CDCl3) δ 8.70 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.53–7.50 (m, 2H), 7.45 (d, J = 7.5 Hz, 1H), 7.36–7.33 (m, 1H), 7.28–7.25 (m, 2H), 3.00 (s, 3H); 13C-NMR (CDCl3) δ 168.0, 153.7, 153.4, 152.3, 136.7, 133.4, 129.9, 129.8, 126.1, 125.9, 122.0, 116.3, 24.1; HRMS (ESI), m/z, 237.1021 [MH+], calcd for C15H13N2O, 237.1028.
6-Chloro-4-phenoxyquinazoline (23). White solid (70% yield); mp 94–97 °C; 1H-NMR (CDCl3) δ 8.77 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.86–7.83 (m, 1H), 7.52–7.49 (m, 2H), 7.36–7.33 (m, 1H), 7.29–7.27 (m, 2H); 13C-NMR (CDCl3) δ 166.1, 154.4, 152.1, 150.1, 134.9, 133.2, 129.8, 129.6, 126.2, 122.7, 121.7, 117.1; HRMS (ESI), m/z, 257.0471 [MH+], calcd for C14H10ClN2O, 257.0482.
7-Chloro-4-phenoxyquinazoline (24). White solid (70% yield); mp 190–192 °C; 1H-NMR (CDCl3) δ 8.78 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 2.0 Hz, 1H), 7.65–7.63 (m, 1H), 7.53–7.50 (m, 2H), 7.36 (t, J = 7.5 Hz, 1H), 7.29–7.27 ppm (m, 2H); 13C-NMR (CDCl3) δ 166.9, 155.5, 152.4, 152.2, 140.5, 129.8, 128.7, 127.2, 126.2, 125.2, 121.8, 114.9; HRMS (ESI), m/z, 257.0471 [MH+], calcd for C14H10ClN2O, 257.0482.
4-Ethoxyquinazoline (25). White solid (54% yield); mp 31–33 °C; 1H-NMR (CDCl3) δ 8.80 (s, 1H), 8.19–8.18 (m, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.84–7.81 (m, 1H), 7.58–7.54 (m, 1H), 4.64 (q, J = 7.0 Hz, 2H), 1.53 (t, J = 7.0 Hz, 3H); 13C-NMR (CDCl3) δ 166.7, 154.5, 150.9, 133.4, 127.7, 126.9, 123.6, 116.8, 63.1, 14.4; HRMS (ESI), m/z, 175.0873 [MH+], calcd for C10H11N2O, 175.0871.
4-Ethoxy-5-methylquinazoline (26). White solid (33% yield); mp 66–69 °C; 1H-NMR (CDCl3) δ 8.72 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.33 (d, J = 7.5 Hz, 1H), 4.61 (q, J = 7.0 Hz, 2H), 2.86 (s, 3H), 1.54 (t, J = 7.0 Hz, 3H); 13C-NMR (CDCl3) δ 167.8, 153.8, 152.6, 136.9, 132.7, 129.3, 125.8, 116.4, 63.1, 24.0, 14.4; HRMS (ESI), m/z, 189.1034 [MH+], calcd for C11H13N2O, 189.1028.
4-Ethoxy-8-methylquinazoline (27). White solid (67% yield); mp 31–32 °C; 1H-NMR (CDCl3) δ 8.84 (s, 1H), 8.04–8.02 (m, 1H), 7.66 (d, J = 7.5 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 4.63 (q, J = 7.0 Hz, 2H), 2.73 (s, 3H), 1.52 (t, J = 7.0 Hz, 3H); 13C-NMR (CDCl3) δ 166.9, 153.4, 150.0, 135.9, 133.5, 126.4, 121.2, 116.6, 62.9, 17.6, 14.3; HRMS (ESI), m/z, 189.1023 [MH+], calcd for C11H13N2O, 189.1028.
7-Chloro-4-ethoxyquinazoline (28). White solid (64% yield); mp 87–88 °C; 1H-NMR (CDCl3) δ 8.76 (s, 1H), 8.08 (d, J = 9.0 Hz, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.49–7.47 (m, 1H), 4.62 (q, J = 7.0 Hz, 2H), 1.51 (t, J = 7.0 Hz, 3H); 13C-NMR (CDCl3) δ 166.6, 155.5, 151.6, 139.6, 127.8, 126.9, 125.0, 115.0, 63.3, 14.3; HRMS (ESI), m/z, 209.0479 [MH+], calcd for C10H10ClN2O, 209.0482.
4-Propoxyquinazoline (29). White solid (48% yield); mp 190–192 °C; 1H-NMR (CDCl3) δ 8.79 (s, 1H), 8.19–8.17 (m, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.83–7.80 (m, 1H), 7.57–7.53 (m, 1H), 4.52 (t, J = 6.5 Hz, 2H), 1.95–1.91 (m, 2H), 1.10 (t, J = 7.5 Hz, 3H); 13C-NMR (CDCl3) δ 166.8, 154.4, 150.9, 133.4, 127.6, 126.9, 123.5, 116.7, 68.7, 22.1, 10.5; HRMS (ESI), m/z, 189.1023 [MH+], calcd for C11H13N2O, 189.1028.

4. Conclusions

In summary, we have successfully developed an HCCP-mediated direct formation of thioethers (4-arylthioquinazolines) from quinazolin-4(3H)-ones and thiophenols in moderate to excellent yields. This method has also been utilized to prepare quinazoline ethers, including 4-aryloxyquinazolines and 4-alkoxyquinazolines, using phenols and sodium alkoxides as the nucleophiles. This direct formation of quinazoline (thio)ethers is mild, convenient, and suitable for a wide range of less expensive nucleophiles. This methodology would facilitate the syntheses of 4-arylthioquinazoline and 4-aryloxyquinazoline derivatives in medicinal chemistry.

Acknowledgments

The authors gratefully acknowledge the financial support of the National Natural Science Foundations of China (NSFC 21146001), and the Key Science and Technology Innovation Team of Zhejiang Province (2009R09002-04).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hori, M.; Iemura, R.; Hara, H.; Ozaki, A.; Sukamoto, T.; Ohtaka, H. Novel 4-phenoxy-2-(1-piperazinyl)quinazolines as potent anticonvulsive and antihypoxic agents. Chem. Pharm. Bull. 1990, 38, 681–687. [Google Scholar] [CrossRef]
  2. Havera, H.J.; Vidrio, H.J. Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents. J. Med. Chem. 1979, 22, 1548–1550. [Google Scholar]
  3. Chao, Q.; Deng, L.; Shih, H.; Leoni, L.M.; Genini, D.; Carson, D.A.; Cottam, H.B. Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α. J. Med. Chem. 1999, 42, 3860–3873. [Google Scholar]
  4. Kung, P.P.; Casper, M.D.; Cook, K.L.; Wilson-Lingardo, L.; Risen, L.M.; Vickers, T.A.; Ranken, R.; Blyn, L.B.; Wyatt, J.R.; Cook, P.D.; et al. Structure−activity relationships of novel 2-substituted quinazoline antibacterial agents. J. Med. Chem. 1999, 42, 4705–4713. [Google Scholar]
  5. Liverton, N.J.; Armstrong, D.J.; Claremon, D.A.; Remy, D.C.; Bardwin, J.J.; Lynch, R.J.; Zhang, G.; Gould, R.J. Nonpeptide glycoprotein IIb/IIIa inhibitors: Substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 483–486. [Google Scholar]
  6. Brunton, S.A.; Stibbard, J.H.A.; Rubin, L.L.; Kruse, L.I.; Guicherit, O.M.; Boyd, E.A.; Price, S. Potent inhibitors of the Hedgehog signaling pathway. J. Med. Chem. 2008, 51, 1108–1110. [Google Scholar]
  7. Smits, R.A.; de Esch, I.J.P.; Zuiderveld, O.P.; Broeker, J.; Sansuk, K.; Guaita, E.; Coruzzi, G.; Adami, M.; Haaksma, E.; Leurs, R. Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach. J. Med. Chem. 2008, 51, 7855–7865. [Google Scholar] [CrossRef]
  8. Sirisoma, N; Pervin, A.; Zhang, H.; Jiang, S.C.; Willardsen, J.A.; Anderson, M.B.; Mather, G.; Pleiman, C.M.; Kasibhatla, S.; Tseng, B.; et al. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J. Med. Chem. 2009, 52, 2341–2351. [Google Scholar] [CrossRef]
  9. Zeng, Z.-S.; He, Q.-Q.; Liang, Y.-H.; Feng, X.-Q.; Chen, F.-E.; Clercq, E.D.; Balzarini, J. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. Bioorg. Med. Chem. 2010, 18, 5039–5047. [Google Scholar]
  10. Nakamura, H.; Onagi, S. Synthesis and biological evaluation of allenic quinazolines using palladium-catalyzed hydride-transfer reaction. Tetrahedron Lett. 2006, 47, 2539–2542. [Google Scholar] [CrossRef]
  11. Castera-Ducros, C.; Azas, N.; Verhaeghe, P.; Hutter, S.; Garrigue, P.; Dumetre, A.; Mbatchi, L.; Laget, M.; Remusat, V.; Sifredi, F.; et al. Targeting the human malaria parasite Plasmodium falciparum: In vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series. Eur. J. Med. Chem. 2011, 46, 4184–4191. [Google Scholar] [CrossRef]
  12. Holladay, M.W.; Campbell, B.T.; Rowbottom, M.W.; Chao, Q.; Sprankle, K.G.; Lai, A.G.; Abraham, S.; Setti, E.; Faraoni, R.; Tran, L.; et al. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 5342–5346. [Google Scholar] [CrossRef]
  13. Rowbottom, M.W.; Faraoni, R.; Chao, Q.; Campbell, B.T.; Lai, A.G.; Setti, E.; Ezawa, M.; Sprankle, K.G.; Abraham, S.; Tran, L.; et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J. Med. Chem. 2012, 55, 1082–1105. [Google Scholar] [CrossRef]
  14. Ple, P.A.; Jung, F.; Ashton, S.; Hennequin, L.; Laine, R.; Morgentin, R.; Pasquet, G.; Taylor, S. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg.Med. Chem. Lett. 2012, 22, 262–266. [Google Scholar]
  15. Yang, S.; Li, Z.; Jin, L.H.; Song, B.A.; Liu, G.; Chen, J.; Chen, Z.; Hu, D.Y.; Xue, W.; Xu, R.Q. Synthesis and bioactivity of 4-alkyl(aryl)thioquinazoline derivatives. Bioorg. Med. Chem. Lett. 2007, 17, 2193–2196. [Google Scholar]
  16. Verhaeghe, P.; Dumetre, A.; Castera-Ducros, C.; Hutter, S.; Laget, M.; Fersing, C.; Prieri, M.; Yzombard, J.; Sifredi, F.; Rault, S.; et al. 4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum. Bioorg. Med. Chem. Lett. 2011, 21, 6003–6006. [Google Scholar] [CrossRef]
  17. Garofalo, A.; Goossens, L.; Baldeyrou, B.; Lemoine, A.; Ravez, S.; Six, P.; David-Cordonnier, M.-H.; Bonte, J.-P.; Depreux, P.; Lansiaux, A.; et al. Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives. J. Med. Chem. 2010, 53, 8089–8103. [Google Scholar]
  18. Harris, C.S.; Hennequin, L.F.; Willerval, O. Three-point variation of a gefinitib quinazoline core. Tetrahedron Lett. 2009, 50, 1600–1602. [Google Scholar] [CrossRef]
  19. Sreedhar, B.; Reddy, P.S.; Reddy, M.A. Catalyst-free and base-free water-promoted SNAr reaction of heteroaryl halides with thiols. Synthesis 2009, 1732–1738. [Google Scholar] [CrossRef]
  20. Wan, Z.K.; Wacharasindhu, S.; Binnun, E.; Mansour, T. An efficient direct amination of cyclic amides and cyclic ureas. Org. Lett. 2006, 8, 2425–2428. [Google Scholar]
  21. Wan, Z.K.; Wacharasindhu, S.; Levins, C.G.; Lin, M.; Tabei, K.; Mansour, T.S. The scope and mechanism of phosphonium-mediated SNAr reactions in heterocyclic amidesand ureas. J. Org. Chem. 2007, 72, 10194–10210. [Google Scholar] [CrossRef]
  22. Shen, Z.L.; Hong, Y.M.; He, X.F.; Mo, W.M.; Hu, B.X.; Sun, N.; Hu, X.Q. Switching the chemoselectivity in the amination of 4-chloroquinazolines with aminopyrazoles. Org. Lett. 2010, 12, 552–555. [Google Scholar]
  23. Shen, Z.L.; He, X.F.; Hong, Y.M.; Hu, X.Q.; Mo, W.M.; Hu, B.X.; Sun, N. One-pot synthesis of 4-aminoquinazolines by hexamethyldisilazane-mediated reaction of quinazolin-4(3H)-ones with amines. Synth. Commun. 2011, 41, 3644–3653. [Google Scholar] [CrossRef]
  24. Shen, Z.L.; He, X.F.; Dai, J.L.; Mo, W.M.; Hu, B.X.; Sun, N.; Hu, X.Q. An efficient HCCP-mediated direct amination of quinazolin-4(3H)-ones. Tetrahedron 2011, 67, 1665–1672. [Google Scholar]
  • Sample Availability: Samples of the compounds 3-17 are available from the authors.

Share and Cite

MDPI and ACS Style

Hu, B.; Zhang, X.; Sheng, L.; Guo, M.; Shen, Z.; Hu, X.; Sun, N.; Mo, W. Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones. Molecules 2013, 18, 5580-5593. https://doi.org/10.3390/molecules18055580

AMA Style

Hu B, Zhang X, Sheng L, Guo M, Shen Z, Hu X, Sun N, Mo W. Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones. Molecules. 2013; 18(5):5580-5593. https://doi.org/10.3390/molecules18055580

Chicago/Turabian Style

Hu, Baoxiang, Xiaochu Zhang, Lili Sheng, Ming Guo, Zhenlu Shen, Xinquan Hu, Nan Sun, and Weimin Mo. 2013. "Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3H)-ones" Molecules 18, no. 5: 5580-5593. https://doi.org/10.3390/molecules18055580

Article Metrics

Back to TopTop